Every Form 4 that Adicet Bio, Inc. (ACET) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACET and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACET filings page.
Adicet Bio, Inc. reported that its Chief Medical Officer, Klickstein Lloyd, received a grant of stock options covering 18,300 shares of common stock at an exercise price of $9.16 per share. According to the award terms, 1/6th of the options vest on each of the next six monthly anniversaries of August 5, 2026, subject to continued service, and the options expire on August 4, 2036.
Adicet Bio President & CEO Chen Schor received a new stock option award covering 55,000 shares of Common Stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
The grant vests over four years, with 1/48th of the options vesting on each of the next 48 monthly anniversaries of the grant date. A portion of the vesting can accelerate if specific performance milestones are met, as long as Schor maintains a service relationship with Adicet Bio on each vesting date.
Adicet Bio, Inc. reported that Chief Scientific Officer Blake Aftab received a grant of stock options covering 55,000 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
These options were granted as compensation and are structured to vest over time. One forty-eighth of the options vests on each of the 48 monthly anniversaries of the grant date, with partial acceleration tied to certain performance milestones, as long as Aftab continues his service relationship with the company.
Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock. The option has an exercise price of $8.10 per share and expires on June 20, 2036. It was awarded as compensation rather than through an open-market purchase or sale.
The option will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Dubin continues serving on the board. Following this grant, he holds 4,200 option shares related to this award.
Adicet Bio director Jeffrey Chodakewitz received a new stock option award covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. Following this grant, he holds stock options for 4,200 underlying shares.
According to the terms, the options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant date, as long as he continues serving on Adicet Bio’s board of directors.
Adicet Bio director Michael Grissinger received a new stock option award covering 4,200 shares of Common Stock. The option was granted at an exercise price of $8.10 per share and expires on June 20, 2036. Following this grant, he holds options for 4,200 shares directly.
The award vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board. This is a compensation-related grant, not an open‑market purchase or sale.
Adicet Bio, Inc. director Andrew Sinclair received a grant of stock options as part of his board compensation. He was awarded 4,200 stock options to purchase Adicet Bio common stock at an exercise price of $8.10 per share. These options expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders after the grant date, subject to his continued service on the board. Following this award, Sinclair holds 4,200 derivative securities linked to Adicet Bio common stock.
Adicet Bio director Katie Peng reported receiving a grant of stock options covering 4,200 shares of Adicet Bio common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. According to the grant terms, all 4,200 options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as she continues serving on the board. After this award, she holds 4,200 stock options directly.
Adicet Bio, Inc. director Lloyd Klickstein received a grant of stock options covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service on the board. This is a routine equity compensation award and does not involve any open-market buying or selling of shares.
Adicet Bio, Inc. reported that an affiliate of RA Capital restructured part of its position through an exchange. On April 27, 2026, RA Capital Healthcare Fund, L.P. entered into an Exchange Agreement to swap 250,000 shares of Adicet Bio common stock for a pre-funded warrant for up to 250,000 common shares at an exercise price of $0.0001 per share, for no additional consideration. Following the transactions, the Fund held 932,624 shares of common stock and 1,402,833 pre-funded warrant shares indirectly. The pre-funded warrant is exercisable immediately, has no expiration date, and includes a 9.99% beneficial ownership limit that prevents exercises above that level when combined with Attribution Parties.
RA Capital–affiliated entities reported open-market purchases of Adicet Bio common stock. RA Capital Healthcare Fund LP, managed by RA Capital Management, L.P., bought 74,577 shares at $7.04 on February 18, 74,268 shares at $7.21 on February 19, and 74,751 shares at $7.27 on February 20. All shares are held directly by the Fund, with RA Capital and individuals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. After the latest trade, the indirect holdings reported for the Fund total 1,182,624 shares, and no derivative securities are listed.
Adicet Bio shareholder update: Investment entities affiliated with OrbiMed reported open-market sales of a total of 104,658 shares of Adicet Bio common stock on April 7–8, 2026, at prices between about $6.29 and $6.53 per share. The Form 4 shows these OrbiMed-related funds continuing to hold sizable indirect positions, including 564,147 shares, 280,640 shares, and 78,499 shares of Adicet Bio common stock through various limited partnerships.
Adicet Bio, Inc. reported that Chief Financial Officer Brian Nicholas received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the vesting terms, 1/48th of the options vest on each monthly anniversary of the grant over forty-eight months, as long as he continues his service relationship with the company. Following this grant, he holds 43,361 stock options directly.
Adicet Bio, Inc. reported that President & CEO Chen Schor received a grant of stock options representing the right to buy 468,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
This award is compensation-related and not an open-market share purchase or sale. The filing notes that one forty-eighth of the options vest each month over 48 months from the grant date, contingent on Mr. Schor continuing his service with the company.
Adicet Bio Chief Medical Officer Julia D. Maltzman was granted stock options covering 72,555 shares of Common Stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. This is a compensation-related award rather than an open-market share purchase.
The filing shows these are held directly and represent 72,555 option shares following the transaction. According to the terms, one forty-eighth of the options vest monthly over 48 months from the grant date, as long as she continues her service with the company.
Adicet Bio, Inc. reported that Chief Technology Officer Don Healey received a grant of stock options covering 43,361 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036. According to the terms, 1/48th of the options vest on each of the 48 monthly anniversaries of the grant date, as long as he continues his service with the company. This is a compensation-related award rather than an open-market share purchase.
Adicet Bio, Inc. Chief Scientific Officer Aftab Blake received a grant of stock options to acquire 72,555 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 24, 2036.
According to the vesting terms, 1/48th of the options vest on each monthly anniversary over the next forty-eight months, as long as Blake continues a service relationship with the company. This is a compensation-related award, not an open-market purchase or sale, and it brings Blake’s directly held option position in this grant to 72,555 derivative securities.
Adicet Bio's Chief Scientific Officer, Aftab Blake, reported a routine share withholding related to equity compensation. On January 24, 2026, 535 shares of common stock were withheld at $8.44 per share to cover tax obligations arising from the vesting of restricted stock units, and this did not involve an open-market sale. Following this withholding, Blake directly beneficially owned 2,981 shares of Adicet Bio common stock. The reported holdings also reflect a 1-for-16 reverse stock split that Adicet Bio effected on December 30, 2025.
Adicet Bio, Inc.’s Chief Technology Officer Don Healey reported an administrative share adjustment related to equity compensation. On 01/24/2026, 535 shares of common stock were withheld by the company at $8.44 per share to cover tax obligations from vesting restricted stock units, rather than being sold on the market. Following this transaction, Healey beneficially owns 3,452 shares of Adicet Bio common stock on a direct basis. The reported holdings also reflect a previously effected 1-for-16 reverse stock split completed on December 30, 2025, which adjusted the share counts.
Adicet Bio President & CEO Schor Chen reported a routine share withholding related to equity compensation. On January 24, 2026, the company withheld 1,755 shares of common stock at $8.44 per share to cover tax obligations from vesting restricted stock units, which is not a market sale.
After this transaction, Chen reports 6,820 common shares held directly. In addition, 2,716 shares are held indirectly through The I. Schor IRRV Trust and 3,339 shares are held indirectly through The C. Schor IRRV Trust, both irrevocable family trusts with independent trustees. The holdings reflect a previously effected 1-for-16 reverse stock split.
Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units. On January 24, 2026, 546 shares of Adicet Bio common stock were withheld at $8.44 per share to cover tax obligations upon RSU vesting, and this did not involve an open-market sale. After this withholding and giving effect to a 1-for-16 reverse stock split completed on December 30, 2025, he beneficially owned 5,145 common shares directly.